- 14.08.2007
- Nabriva Therapeutics announced today commencement of a clinical phase I program for its topical pleuromutilin antibiotic BC-7013
- 27.06.2007
- Nabriva Therapeutics has appointed Dr. Robert Moellering to its Supervisory Board.
- 05.06.2007
- Dr. John Goka has just joined the Nabriva management team as Chief Medical Officer.
© Nabriva Therapeutics Forschungs GmbH